Protagenic Therapeutics, Inc.\new Shareholders' Equity
Protagenic Therapeutics, Inc.\new (PTIX) had Shareholders' Equity of $1.72 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-19
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.72M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $2.62M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$2.39M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$4.70M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $1.72M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $2.62M 10-Q · filed 2026-08-19 | |
| 2025-12-31 | -$2.39M 10-Q · filed 2026-03-09 | |
| 2025-09-30 | -$4.70M 10-Q · filed 2026-03-09 | |
| 2025-06-30 | -$3.97M 10-Q · filed 2026-08-19 | |
| 2025-03-31 | -$4.95M 10-Q · filed 2026-08-19 | -$88.33K 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$3.32M 10-Q · filed 2026-03-09 | $1.01M 10-K · filed 2025-03-31 |
| 2024-09-30 | -$2.47M 10-Q · filed 2026-03-09 | $719.01K 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$1.75M 10-Q · filed 2026-03-09 | $792.52K 10-Q · filed 2024-08-14 |
| 2024-03-31 | -$1.79M 10-K · filed 2026-08-14 | $2.13M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $3.67M 10-Q · filed 2025-05-13 | |
| 2023-09-30 | $4.15M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $5.41M 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $6.41M 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $6.92M 10-K · filed 2025-03-31 | |
| 2022-09-30 | $7.38M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $8.26M 10-Q · filed 2023-11-14 | |
| 2022-03-31 | $8.72M 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $9.94M 10-K/A · filed 2024-05-14 | |
| 2021-09-30 | -$10.37M 10-Q · filed 2022-11-14 | $10.37M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $10.80M 10-Q · filed 2022-11-14 | |
| 2021-03-31 | -$1.98M 10-Q · filed 2022-11-14 | |
| 2020-12-31 | -$1.15M 10-K · filed 2023-03-31 | |
| 2020-09-30 | -$1.02M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$659.11K 10-Q · filed 2021-11-15 | -$746.08K 10-Q · filed 2020-08-14 |
| 2020-03-31 | -$585.92K 10-Q · filed 2021-11-15 | |
| 2019-12-31 | -$634.37K 10-K · filed 2022-04-07 | |
| 2019-09-30 | -$363.74K 10-Q · filed 2020-11-16 | |
| 2019-06-30 | -$379.48K 10-Q · filed 2020-11-16 | |
| 2019-03-31 | -$361.82K 10-Q · filed 2020-11-16 | |
| 2018-12-31 | -$210.88K 10-K · filed 2021-03-25 | |
| 2018-09-30 | $323.03K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $559.88K 10-Q · filed 2019-11-14 | |
| 2018-03-31 | $964.90K 10-Q · filed 2019-11-14 | |
| 2017-12-31 | $1.22M 10-K · filed 2020-04-29 | |
| 2017-09-30 | $1.68M 10-Q · filed 2017-11-13 | |
| 2017-06-30 | $1.88M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $2.18M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $2.48M 10-K · filed 2019-03-29 | |
| 2016-09-30 | $2.94M 10-Q · filed 2016-11-17 | |
| 2016-06-30 | $3.19M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $3.02M 10-Q · filed 2016-07-25 | |
| 2015-12-31 | -$667.22K 10-K · filed 2018-04-02 | -$786.00K 10-Q · filed 2016-03-11 |
| 2015-09-30 | -$628.00K 10-Q · filed 2015-11-13 | |
| 2015-06-30 | -$497.00K 10-Q · filed 2016-03-11 | |
| 2015-03-31 | -$385.00K 10-Q · filed 2015-05-11 | |
| 2014-12-31 | -$121.35K 8-K/A · filed 2016-07-12 | -$266.00K 10-Q · filed 2015-02-06 |
| 2014-09-30 | -$133.00K 10-Q · filed 2014-11-13 | |
| 2014-06-30 | -$21.00K 10-K · filed 2015-09-25 | |
| 2013-12-31 | -$120.59K 10-K/A · filed 2017-05-08 | $252.30K 8-K/A · filed 2016-07-12 |
| 2011-09-30 | -$5.65M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | -$1.11M 10-Q/A · filed 2011-09-07 | |
| 2010-12-31 | $8.17M 10-Q · filed 2011-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |